---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-017192"
form_type: "8-K"
ticker: "CLYM"
cik: "0001768446"
company_name: "Climb Bio, Inc."
filed_at: "2022-08-15T23:59:59+00:00"
generated_at: "2026-06-23T23:58:19.543588+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Eliem Therapeutics Q2 net loss $14.6M; discontinues ETX-810 Phase 2a after failure

## Summary
- Net loss of $14.6M for Q2 2022 vs $8.7M in Q2 2021; cash, equivalents, securities $134.7M.
- ETX-810 discontinued after failing primary endpoint in lumbosacral radicular pain Phase 2a.
- Initiated Phase 1 PK trial for ETX-155; results expected Q4 2022; Phase 2a MDD planned Q1 2023.
- Cash runway now expected to fund operations into 2025 due to ETX-810 discontinuation.
- R&D expenses $8.8M (up from $5.8M YoY); G&A $4.9M (up from $2.9M YoY).

## SEC filing metadata
- accession: 0000950170-22-017192
- form_type: 8-K
- ticker: CLYM
- cik: 0001768446
- company_name: Climb Bio, Inc.
- filed_at: 2022-08-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768446/000095017022017192/0000950170-22-017192-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768446/000095017022017192/elym-20220815.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-017192
- JSON: https://secwatch.observer/filing/0000950170-22-017192.json
- Plain text: https://secwatch.observer/filing/0000950170-22-017192.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.